Key result
Polymer-free everolimus DES cuts in-stent restenosis to ~9% vs. bare-metal and coated stents.
Answers are grounded in this paper and cite their sources.
The aim of this study was to fabricate a novel polymer-free everolimus-eluting stent with nanostructure using a femtosecond laser (FSL). The stent were coated with everolimus (EVL) using FSL and electrospinning processes. The surface was rendered hydrophobic, which negatively affected both platelet adhesion (82.1%) and smooth muscle cell response. Animal study was performed using a porcine coronary restenosis model. The study groups were divided into 1) bare metal stent (BMS), 2) poly(L-lactide) (PLA)-based EVL drug eluting stent (DES), 3) commercial EVL-eluting DES, and 4) FSL-EVL-DES. After four weeks of stent implantation, various analyses were performed. Quantitative analysis showed that the amount of in-stent restenosis was higher in the BMS group (BMS; 27.8 ± 2.68%, PLA-based DES; 12.2 ± 0.57%, commercial DES; 9.8 ± 0.28%, and FSL-DES; 9.3 ± 0.25%, n = 10, p < 0.05). Specifically, the inflammation score was reduced in the FSL-DES group (1.9 ± 0.39, n = 10, p < 0.05). The increment in re-endothelialization in the FSL-DES group was confirmed by immunofluorescence analysis. Taken together, the novel polymer-free EVL-eluting stent fabricated using FSL can be an innovative DES with reduced risk of ISR, thrombosis, and inflammation.
No takes yet. Share an insight, caveat, or question.
Bae et al. (2018) studied Porcine coronary restenosis model. Femtosecond laser-fabricated polymer-free everolimus-eluting stent (FSL-EVL-DES) vs. Bare metal stent (BMS), poly(L-lactide) (PLA)-based everolimus DES, and commercial everolimus DES was evaluated on In-stent restenosis at 4 weeks (p=<0.05). Femtosecond laser polymer-free everolimus DES reduced in-stent restenosis compared with bare metal, PLA-based, and commercial stents.
Synapse has enriched 10 related papers. Consider them for comparative context: